Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments and have been licensed ...

When evaluating a patient with RFL, it is important for the clinician to be aware of the etiology and pathophysiology of common causative syndromes, as well as diagnostic procedures and treatment ...

Traci L. Powell, MSN, NNP; Leslie Parker, PhD, NNP-BC; Cynthia F. Dedrick, PhD, NNP; Christina M. Barrera, MSN, NNP; Dawn Di Salvo, MSN, NNP, CLC; Felicia Erdman, MSN ...